A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.
about
Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemnessDesign, synthesis, evaluation, and structure of vitamin D analogues with furan side chainsCooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemiaVitamin D: considerations in the continued development as an agent for cancer prevention and therapy.Murine Pancreatic Acinar Cell Carcinoma Growth Kinetics Are Independent of Dietary Vitamin D Deficiency or Supplementation.Chemoprevention strategies for pancreatic cancerVitamin D and GI cancers: shedding some light on dark diseasesVitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.Review article: chemotherapy for pancreatic cancer.A new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1α,25-dihydroxyvitamin D₃.Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.Vitamin D and cancer: clinical aspects.A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinomaVitamin d and its role in cancer and immunity: a prescription for sunlight.Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.Mechanism of UV-related carcinogenesis and its contribution to nevi/melanomaVitamin D and human health: lessons from vitamin D receptor null mice.Vitamin d and pancreatic cancer-an update.Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications.Vitamin D for the prevention and treatment of pancreatic cancer.The future of vitamin D analogs.The role of vitamin D in cancer prevention and treatment.Immunomodulation using agonists and antagonists: potential clinical applications.The role of vitamin D in cancer prevention and treatment.Current progress in using vitamin D and its analogs for cancer prevention and treatment.Vitamin D receptor agonists' anti-inflammatory properties.Vitamin D in cancer chemoprevention.Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.Eldecalcitol (ED-71), an analog of 1α,25(OH)2D3, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) aTargeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer.Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer.Vitamin D analog EB1089 induces apoptosis in a subpopulation of SGC-7901 gastric cancer cells through a mitochondrial-dependent apoptotic pathway.BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents.Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3.A 5'-distal element mediates vitamin D-inducibility of PDGF-A gene transcription.E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations.
P2860
Q27346674-76378029-2049-452A-BD26-9CFA762647E8Q27676147-5F7E49E1-FDD6-40ED-A69E-A501F6583303Q33668436-33B4164F-62FC-482D-BD00-64AF860F8AEAQ33802601-48D08D2D-66DB-4F43-9C3A-BEFB629E5C11Q33845341-FB852868-EAA2-4F79-894A-F2E11BBAF963Q34082960-932480C5-8563-4307-AA71-DC680216AA96Q34357880-3BB6E161-B83A-445F-B475-F02E53A25791Q34621641-202490C1-80AD-4E24-9090-069481C984ABQ34756280-15C67DA2-64EF-46DD-B4A0-011E5013D4DCQ34778161-5C1B6EEE-BACE-4274-8427-EA3E8F36DC24Q35599597-C8C2E0DA-9CD6-4485-B6E7-D2E1D82FB752Q36008987-365F7F47-40BD-4E98-81C0-972399D29AEEQ36279579-758E2CB7-0478-4FEC-BE72-80EE9862B5E4Q36509508-D5B7CE10-955F-4BA4-80BA-8644E648DA02Q36670965-92050609-EC4F-4FB5-ADA5-5804403DCB8BQ36824458-081FFF1B-AD63-4F3A-BE83-582CB5BF9E8DQ36906268-25971DDB-E92C-4FAA-967E-4CF733896BBDQ36930745-5BFEE7D7-E262-4B19-B3AB-CFF72C4913BCQ36973933-C863322E-82B5-4DAD-AB31-B98989D16F6DQ37129757-562A4538-7D82-463E-8DB5-8766E1ECB74EQ37226982-8B5E3FAC-3D8D-4841-9084-0BECE9C899E5Q37554201-AA7FFAF5-5273-46CE-B6E8-074C7ED33B0AQ37695300-2C27C4B8-3AAB-4EAC-A143-E1511A0702B3Q37761548-C0E270E8-E736-4B4B-B78B-E00775B6D4E4Q37965728-BAF89134-A83C-4457-997B-C0D5EF5D690AQ38004753-4BF7BC3B-E9C0-42D8-8D97-7B587678562AQ38020247-26EDEA51-9B2B-4772-A2C4-08FFCE169955Q38206253-FB8B865F-F92B-4FAE-8EBC-FF3860B37CD1Q38412880-409F95BE-526A-4062-837F-42DCEF96A514Q38633074-8AD9198E-A372-41B1-A16A-528DBA4F8E0DQ38697291-AE7CA376-F952-405D-B141-FF0D9EF3AB34Q38708376-D938C8C1-FDBF-4A5A-AA85-4B058D485843Q38914179-5B350F35-569B-4675-8E54-C2CB22CDE8FAQ39085353-7EAB770D-02BF-4D7D-B3AE-B09868BA0253Q39381021-281767B9-1473-435D-A62A-B15CF262424DQ40678561-F61DCF07-3DD8-4BF5-A1F8-AD5E9DB20A87Q42455160-07369C2A-799E-4482-A384-20DCB050B98BQ46735000-A3B09AE1-3748-466D-B89B-8BD9A4BA33FE
P2860
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@ast
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@en
type
label
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@ast
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@en
prefLabel
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@ast
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@en
P2093
P2860
P356
P1476
A phase II trial of the vitami ...... inoperable pancreatic cancer.
@en
P2093
D A Anthoney
J S de Bono
K J Hamberg
K W Colston
T R J Evans
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600162
P407
P577
2002-03-01T00:00:00Z
P5875
P6179
1026341603